General Neurology
High-pressure neurologic syndrome
Apr. 30, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
The mitochondrial enzyme D-2 hydroxyglutarate dehydrogenase catalyzes the irreversible oxidation of D-2-hydroxyglutarate; inactivation of this enzyme by mutations causes D-2-hydroxyglutaric aciduria type I. D-2-hydroxyglutarate can be produced from alpha-ketoglutarate by four different enzymes. Hydroxyacid-oxoacid transhydrogenase (HOT) oxidizes 4-hydroxybutyrate using alpha-ketoglutarate as an electron acceptor. 3-P- glycerate dehydrogenase, an enzyme involved in the serine synthesis pathway (not shown), has side activity on alpha-ketoglutarate due to the structural similarity of alpha-ketoglutarate with the normal product of this enzyme (ie, 3-phosphohydroxypyruvate). Mutated forms of IDH2 in D-2-hydroxyglutaric aciduria type II and mutated forms of IDH1 and IDH2 in glioblastomas and various other cancers efficiently catalyze the reduction of alpha-ketoglutarate to D-2-hydroxyglutarate; in this situation, the metabolic capacity of D-2-hydroxyglutarate dehydrogenase is exceeded, and D-2-hydroxyglutarate accumulates. (Source: Veiga-da-Cunha M, Van Schaftingen E, Bommer GT. Inborn errors of metabolite repair. J Inherit Metab Dis 2020;43[1]:14-24. Creative Commons Attribution License.)